ANA Therapeutics ( SOSV Accelerator)
Funding Details
Awarder
SOSV
Date Award
May 13, 2024
Vertical
Therapeutics
Funding URL
View Funding Page
Company Info
Market
COVID-19 Treatment
Location
United States
Company Description

ANA Therapeutics developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a treatment for COVID-19. ANA Therapeutics was acquired by NeuroBo Pharmaceuticals in 2020.

Links
Website
Back to HomeBack to Therapeutics DealsView Funding Announcement